Trial reportJournal of neurology2010
Alemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy.
Trial report in Journal of neurology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 78 citations in OpenAlex.
- Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy.The Cochrane database of systematic reviews · 2017Pooled it
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): A Comprehensive Review of Types, Pathophysiology, and Treatment Approaches.Brain and behavior · 2026Review
- Advances in the treatment of autoimmune nodopathy: based on treatment strategies of CIDP.Frontiers in immunology · 2026Review
- Classical Complement Pathway Inhibition in a "Human-On-A-Chip" Model of Autoimmune Demyelinating Neuropathies.Advanced therapeutics · 2022Article
- Immunoglobulin and Monoclonal Antibody Therapies in Guillain-Barré Syndrome.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022Review
- Progress in Hematopoietic Stem Cell Transplantation for CIDP.International journal of medical sciences · 2020Review
- Immune-mediated neuropathies.Nature reviews. Disease primers · 2018Review
- Novel pathomechanisms in inflammatory neuropathies.Journal of neuroinflammation · 2017Review
- Immunotherapy in Peripheral Neuropathies.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2016Review
- Future perspectives in target-specific immunotherapies of myasthenia gravis.Therapeutic advances in neurological disorders · 2015Review
- Treatment of chronic inflammatory demyelinating polyneuropathy.Current neurology and neuroscience reports · 2015Review
- Disease-modifying therapy in multiple sclerosis and chronic inflammatory demyelinating polyradiculoneuropathy: common and divergent current and future strategies.Clinical and experimental immunology · 2014Review
- Is dosing of therapeutic immunoglobulins optimal? A review of a three-decade long debate in europe.Frontiers in immunology · 2014Review
- Chronic inflammatory demyelinating polyneuropathy.Current treatment options in neurology · 2013Article
- Review
- Alemtuzumab: evidence for its potential in relapsing-remitting multiple sclerosis.Drug design, development and therapy · 2013Review
- An update on the management of chronic inflammatory demyelinating polyneuropathy.Therapeutic advances in neurological disorders · 2012Article
- Chronic inflammatory demyelinating polyradiculoneuropathy: from bench to bedside.Seminars in neurology · 2012Review
- Advances in the treatment of chronic inflammatory demyelinating neuropathies in 2010.Journal of neurology · 2011Review
- Advances in the diagnosis, pathogenesis and treatment of CIDP.Nature reviews. Neurology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 2 countries.
Funding
Abstract
Chronic inflammatory demyelinating polyneuropathy (CIDP) is an idiopathic immune mediated neuropathy causing demyelination and conduction block thought to occur as the result of an aberrant autoimmune response resulting in peripheral nerve inflammation mediated by T cells and humoral factors. Diagnosis commonly prompts initial treatment with steroids or intravenous immunoglobulin (IVIG) on which 5-35% subsequently become dependent to maintain function. Despite a number of small scale trials, the role for alternative long-term immunosuppression remains unclear. Alemtuzumab is a humanised monoclonal antibody targeting the CD52 antigen present on the surface of lymphocytes and monocytes. A single intravenous infusion results in rapid and profound lymphopoenia lasting >12 months. We report its use and clinical outcome in a small series of patients with severe IVIG-dependent CIDP. Seven patients (4 Males; 3 Females) who had failed to respond to conventional immunosuppression were treated in 5 centres receiving 9 courses of alemtuzumab (dose range 60-150 mg). Following treatment, mean monthly IVIG use fell 26% from 202 to 149 g and IVIG administration frequency from 22 to 136 days. Two patients had prolonged remission, two patients had a partial response and no clear benefit was observed in the remaining three patients (2 Males, 1 Females). Responding patients had a younger age at onset (19.5 years) and shorter disease duration than non-responders. Three patients developed autoimmune disease following treatment. Alemtuzumab may offer an alternative treatment for a subset of early onset IVIG dependent CIDP patients failing conventional immunosuppressive agents, but concerns about toxicity may limit its use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.